Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visudyne Combo Therapies Are QLT’s Focus As Competition Comes Into View

Executive Summary

QLT is working to position Visudyne as part of combination therapies for age-related macular degeneration in the face of stiffening competition

You may also be interested in...



OSI Takes Wait-And-See Approach To Lucentis Impact On Macugen

An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said

Macugen/Visudyne Concomitant Use Appears Safe – Cmte; QLT Wants Trials

Concomitant use of Pfizer/Eyetech's Macugen (pegaptanib) with Novartis/QLT's Visudyne (verteporfin) does not pose safety concerns, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee concluded Aug. 27

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel